Prelude Therapeutics Incorporated (PRLD) is a clinical-stage precision oncology company developing small-molecule cancer therapies targeting epigenetic and DNA-damage-response pathways. After a sharp pullback in the second half of 2026, the stock trades far below the average target set by Wall Street analysts, raising a straightforward question for investors: can PRLD climb back toward a $9.20 stock price target?
PRLD has a small but active analyst following. Reviewing five individually attributable targets gives a calculated average analyst price target of $9.20. The individual targets are J.P. Morgan's $12.00 (Overweight, initiated September 17, 2026), Morgan Stanley's $11.00 (Equal Weight), D. Boral Capital's $9.00 (Buy, initiated May 4, 2026), H.C. Wainwright's $8.00 (Buy, reiterated October 13, 2026 after being raised from $5.00 in April), and Citizens JMP's $6.00 (Market Outperform, raised from $3.00 in March 2026).
The low-to-high range of roughly $6.00 to $12.00 is exceptionally wide for a stock this size, and the difference between the most cautious and most optimistic views is meaningful. H.C. Wainwright has been the most consistent cheerleader for the name, while Morgan Stanley's Equal Weight launch signals a more measured view. D. Boral Capital pointed to a "deep pipeline, emerging clinical validation, and multiple near-term catalysts," and separately cited validation of the company's JAK2 franchise through a program-specific agreement with Incyte.
PRLD recently changed hands near $3.32 per share, down from roughly $4.50 to $4.75 earlier in 2026. The stock's 52-week range has been extremely wide — spanning roughly $1 to nearly $7 — underscoring the volatility typical of a pre-revenue biotech. To reach the $9.20 central target, the share price would need to advance approximately 177%, a move that can only be described as very large.
A path toward that level would almost certainly depend on clinical execution rather than near-term financial results. Prelude is advancing PRT7732, an oral SMARCA2 degrader, in a Phase 1 trial in biomarker-selected SMARCA4-mutated cancers, and disclosed preclinical data for PRT13722, a KAT6A degrader, at the AACR Annual Meeting in April 2026, with an IND (investigational new drug application) filing planned for mid-2026. The company also holds a partnership with AbCellera on precision antibody-drug conjugates. Because the company is pre-revenue in a commercial sense, valuation is driven by the perceived probability of these programs succeeding.
PRLD trades in the low $3s, well below its prior 2026 peak and toward the lower portion of its wide 52-week range. The lowest analyst target of $6.00 sits near the stock's earlier highs, meaning even the most conservative target requires the shares to roughly double. The $8.00–$9.00 zone and the $12.00 level are far above any recent trading, so there is limited nearby resistance to guide the path; the dominant technical story is simply how far the stock has fallen from its highs.
Analyst price targets typically reflect a 12-month research horizon, though individual firms may differ, and for a clinical-stage biotech the timing of catalysts matters more than the calendar. Investors should monitor the IND filing and Phase 1 initiation for PRT13722, any new data from the SMARCA2 degrader program, quarterly cash burn and financing announcements, and any analyst target revisions or rating changes. Partnering decisions, such as the status of the CDK9 program PRT2527 and the AbCellera collaboration, are also relevant.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like PRLD, this kind of automated scanning can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review alone. Traders seeking an edge in timing entries and exits can explore these signals to complement their own research.
The $9.20 central target is a calculated average of five verified analyst price targets spanning $6.00 to $12.00 — an unusually broad spread that itself signals real uncertainty about how much Prelude's oncology pipeline is worth. From a recent price near $3.32, reaching that level would require roughly a 177% gain, a very large move that hinges on successful clinical execution, additional positive data, and renewed investor appetite for pre-revenue biotech. The pipeline catalysts are tangible, and analysts have been raising targets through 2026, but the stock's persistent losses, clinical risk, and recent downward slide are equally real. Whether PRLD can reach $9.20 ultimately depends on data the company has not yet produced, not on the target itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PRLD has been loosely correlated with SRPT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRLD jumps, then SRPT could also see price increases.
| Ticker / NAME | Correlation To PRLD | 1D Price Change % | ||
|---|---|---|---|---|
| PRLD | 100% | +3.40% | ||
| SRPT - PRLD | 40% Loosely correlated | -3.18% | ||
| MLTX - PRLD | 35% Loosely correlated | +3.20% | ||
| VSTM - PRLD | 35% Loosely correlated | -1.39% | ||
| RNTX - PRLD | 35% Loosely correlated | +4.99% | ||
| AMRN - PRLD | 35% Loosely correlated | +0.26% | ||
More | ||||